ArticleBriefings in bioinformatics2025
SARITA: a large language model for generating the S1 subunit of the SARS-CoV-2 spike protein.
Article in Briefings in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- From sequences to strategies: Early detection of new SARS-CoV-2 variants via genetic distance to reduce hospitalizations.PLoS computational biology · 2026Article
- PRIME: An evaluation framework for protein representation inference and generalization in viral mutation space.BMC genomics · 2026Article
- Protein language models enable accurate viral host range prediction.Scientific reports · 2026Article
- Zoon0PredV: Potential Virus Species Crossover Prediction Using Convolutional Neural Networks and Viral Protein Sequence Patterns.Bioinformatics and biology insights · 2026Article
- vir2vec: A Viral Genome-Wide Viral Embedding.bioRxiv : the preprint server for biology · 2025Article
- Predictive and interpretable machine learning for COVID-19 resurgences: the role of SARS-CoV-2 variants in the post-pandemic era.BMC infectious diseases · 2025Article
- TransFactor-prediction of pro-viral SARS-CoV-2 host factors using a protein language model.Bioinformatics (Oxford, England) · 2025Article
- Multifractal analysis and support vector machine for the classification of coronaviruses and SARS-CoV-2 variants.Scientific reports · 2025Article
- Fine-tuning protein language models unlocks the potential of underrepresented viral proteomes.PeerJ · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe COVID-19 pandemic has caused over 776 million infections and 7 million deaths globally between December 2019 and November 2024. Since the emergence of the original Wuhan strain, SARS-CoV-2 has evolved into multiple variants-including Alpha, Delta, and Omicron-primarily through mutations in the Spike glycoprotein. The S1 subunit, which binds the human angiotensin-converting enzyme 2 (ACE2) receptor, mutates frequently and plays a key role in infectivity and immune escape, while the more conserved S2 subunit mediates membrane fusion. Anticipating future mutations is essential for guiding vaccine design and therapeutic strategies. Generative Large Language Models (LLMs) have shown promise in protein sequence modeling due to their capacity to produce realistic and functional synthetic sequences. Here, we introduce SARITA, a GPT-3-based LLM with up to 1.2 billion parameters, fine-tuned via continual learning on the protein model RITA trained on 107 017 high-quality SARS-CoV-2 Spike sequences (up to March 1st 2021) to generate high-quality synthetic SARS-CoV-2 Spike S1 subunits.
resultsSARITA is able to generate realistic, full-length synthetic S1 subunits starting from a 14-amino-acid prompt. When evaluated on unseen sequences collected between March 2021 and November 2023-including major Variants of Concern (VOCs) such as Delta and Omicron, and Variants of Interest such as Iota-SARITA outperforms baseline and state-of-the-art LLMs in terms of sequence quality, biological plausibility, and similarity to real-world viral evolution. SARITA generates high-quality sequences in over 97% of cases, with markedly lower False Mutation Rate and higher similarity scores (PAM30, Levenshtein distance) compared to alternative approaches. It also accurately reproduces key mutations characteristic of future variants-such as L212I, R158L, T95P, and E406K-which were not present in the training data but emerged later in VOCs like Omicron and Delta. Structure-based analysis confirms the functional plausibility of these substitutions, with ΔΔG values within experimentally supported thresholds for ACE2 and antibody binding. Furthermore, SARITA anticipates immune-evasive mutations and accurately captures the positional and statistical distribution of mutations found in post- March 1st 2021 variants, highlighting its potential as a predictive tool for viral evolution.
conclusionThese results indicate the potential of SARITA to predict future SARS-CoV-2 S1 evolution, potentially aiding in the development of adaptable vaccines and treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.